First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602

BACKGROUND: A cytotoxic chemotherapeutic regimen is not routinely recommended for frail elderly patients with unresectable colorectal cancer (CRC) because of susceptibility to treatment. Panitumumab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR). Use of panitumumab as...

Descripción completa

Detalles Bibliográficos
Autores principales: Terazawa, Tetsuji, Kato, Takeshi, Goto, Masahiro, Sakai, Daisuke, Kurokawa, Yukinori, Shimokawa, Toshio, Matsubara, Yoshihiro, Satoh, Taroh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593562/
https://www.ncbi.nlm.nih.gov/pubmed/31238905
http://dx.doi.org/10.1186/s12885-019-5821-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593562/
https://www.ncbi.nlm.nih.gov/pubmed/31238905
http://dx.doi.org/10.1186/s12885-019-5821-z

Ejemplares similares